SCHERING, TAP HALT TRIAL OF DRUG FOR UTERINE GROWTHS

Schering AG, Germany's third-largest drugmaker, stopped a trial of its Asoprisnil treatment for benign uterine growths after some patients developed side effects that required surgery to reverse. The setback is the third this year for the Berlin-based company, which already said approval of its Bonefos cancer drug and its PTK colon cancer medicine will be delayed. The shares fell 2.24 euros, or 4.2 percent, to 50.95 euros at the close of trading in Frankfurt after declining as much as 4.8 percent.

Bloomberg (http://www.bloomberg.com/apps/news?pid=10000100&sid=afzw61LGtTbE&refer=germany)